Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Prithviraj Bose(The University of Texas MD Anderson Cancer Center), Pankit Vachhani(Roswell Park Comprehensive Cancer Center), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center)
Current Treatment Options in Oncology
March 1, 2017
10.1007/s11864-017-0456-2
Cited by 239

Abstract

Related Papers

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer et al.|Journal of Clinical Oncology|2001|889
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith, Qi Wang, Chen-Shan Chin et al.|Nature|2012|744
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
Hui Yang, Carlos E. Bueso‐Ramos, Courtney DiNardo et al.|Leukemia|2013|679
Targeting Epigenetic Readers in Cancer
Mark A. Dawson, Tony Kouzarides, Brian J.P. Huntly|New England Journal of Medicine|2012|395
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition
Nathalie Jacque, Anne Marie Ronchetti, Clément Larrue et al.|Blood|2015|382